Compare Amylx Pharmaceuticals Inc (AMLX) vs ProShares UltraShort Bloomberg Natural Gas ETF (KOLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs ProShares UltraShort Bloomberg Natural Gas ETF — how do they compare? Amylx Pharmaceuticals Inc trades at $23.65 (market cap $2.53B), while ProShares UltraShort Bloomberg Natural Gas ETF trades at $28.49. The key difference: Amylx Pharmaceuticals Inc is trading nearer its 52-week high, ProShares UltraShort Bloomberg Natural Gas ETF nearer its low. Which is the better fit depends on your goals.
| AMLX | KOLD | |
|---|---|---|
Market Cap | $2.53B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $24.19 | $49.39 |
52-Week Low | $7.82 | $13.58 |
Enterprise Value | $2.28B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $22.82, down 5.66% on the day, with a bullish technical signal from moving averages and key support at $22. The company reported a net loss of -$144.74M for 2025, with negative ROE and ROA, but holds a $250.8M cash runway into 2028. The pivotal Phase 3 LUCIDITY trial for avexitide is set for a late August/early September 2026 readout, a key near-term catalyst.
Analyst consensus is strongly bullish with a $30.00 price target, though recent earnings misses and negative cash flow from operations in 2026 pose risks. The stock's outlook hinges on successful clinical trial results and the subsequent regulatory pathway for its lead endocrine asset.
KOLD, trading at $31.22, is down 2.19% over the past 24 hours. The technical outlook is bullish based on moving averages, with key support at $30 and resistance at $32. Recent news highlights natural gas market volatility, with futures influenced by weather forecasts and LNG export flows. Financial ratios are unavailable in the provided data, limiting fundamental assessment.
The stock's near-term trajectory hinges on natural gas price movements and demand shifts. While technical indicators suggest upward momentum, the lack of fundamental data and exposure to commodity price swings present risks. Investors should weigh the ETF's leveraged structure against market volatility for tactical positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About ProShares UltraShort Bloomberg Natural Gas ETF
KOLD is an inverse leveraged ETF that seeks to provide two times (2x) the inverse daily performance of the Bloomberg Natural Gas Subindex. It is designed for investors looking to profit from falling natural gas prices.
Read more on KOLD →
